| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.11. | Silo Pharma selects Allucent to support PTSD treatment IND submission | 3 | Investing.com | ||
| 17.11. | Silo Pharma beauftragt Allucent mit IND-Antrag für PTBS-Medikament | 1 | Investing.com Deutsch | ||
| 17.11. | Silo Pharma, Inc.: Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD | 179 | GlobeNewswire (Europe) | SARASOTA, FL, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company,... ► Artikel lesen | |
| 13.11. | Silo Pharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 29.10. | Silo Pharma, Inc.: Silo Pharma Selects Alphaledger's T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain | 2 | GlobeNewswire (USA) | ||
| 24.10. | Aktionäre von Silo Pharma stimmen Änderung des Aktienplans und Reverse-Split zu | 3 | Investing.com Deutsch | ||
| SILO PHARMA Aktie jetzt für 0€ handeln | |||||
| 24.10. | Silo Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.10. | Silo Pharma advances PTSD treatment, expands into crypto assets | 3 | Investing.com | ||
| 23.10. | Silo Pharma: Fortschritte bei PTBS-Therapie und strategischer Einstieg in Krypto-Assets | - | Investing.com Deutsch | ||
| 23.10. | Silo Pharma, Inc.: Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program | 170 | GlobeNewswire (Europe) | Significant milestones are approaching in drug development; additional digital asset purchases expected Preparation for FDA IND application expected to commence before year-end SARASOTA, FL, Oct.... ► Artikel lesen | |
| 08.10. | Silo Pharma adds bitcoin to growing crypto treasury strategy | 1 | Investing.com | ||
| 08.10. | Silo Pharma erweitert Krypto-Treasury-Strategie um Bitcoin | - | Investing.com Deutsch | ||
| 08.10. | Silo Pharma, Inc.: Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company's Commitment to Multi-Chain Growth | 141 | GlobeNewswire (Europe) | SARASOTA, FL, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company... ► Artikel lesen | |
| 06.10. | Silo Pharma acquires ResearchCoin crypto tokens | 1 | Seeking Alpha | ||
| 06.10. | Silo Pharma, Inc.: Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci) | 217 | GlobeNewswire (Europe) | Company invests in DeSci blockchain innovation and purchases native coin of ResearchHub, a decentralized science platform co-founded by Coinbase CEO, Brian Armstrong SARASOTA, FL, Oct. 06, 2025 (GLOBE... ► Artikel lesen | |
| 01.10. | Silo Pharma schließt registrierte Direktplatzierung über 2,5 Millionen US-Dollar ab | 1 | Investing.com Deutsch | ||
| 01.10. | Silo Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.10. | Silo Pharma, Inc.: Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | 2 | GlobeNewswire (USA) | ||
| 30.09. | Silo Pharma raises $2.5 million in registered direct offering | 1 | Investing.com | ||
| 30.09. | Silo Pharma, Inc.: Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | 1 | GlobeNewswire (USA) |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,00 | -0,06 % | Alarm bei Evotec! BioNTech und Vidac Pharma mit Erfolgen beim Kampf gegen Krebs! Analysten raten zum Kauf! | Bei Evotec läuten die Alarmglocken. Ein Großaktionär ist komplett beim deutschen Biotech-Unternehmen ausgestiegen. Dabei notiert das Wertpapier auf dem Niveau von 2016. Einen Meilenstein hat dagegen... ► Artikel lesen | |
| CUREVAC | 3,498 | -1,96 % | BioNTech SE: BioNTech schließt Übernahme von CureVac N.V. samt damit verbundener Nachangebotsfrist ab und stärkt so die einzigartige Position im mRNA-Feld | BioNTech hat das Umtauschangebot zur Übernahme von CureVac abgeschlossenDie Übernahme von CureVac ergänzt BioNTechs Fähigkeiten und unternehmenseigene Technologien im Bereich mRNA-Design, Verabreichungsformulierungen... ► Artikel lesen | |
| AMGEN | 281,30 | +0,59 % | ROUNDUP/Aktien New York Schluss: Erholung geht weiter | NEW YORK (dpa-AFX) - Die US-Börsen haben sich am Freitag weiter von ihrem jüngsten Rücksetzer erholt. Eine Jahresendrally sei nach wie vor möglich, sagte ein Investmentexperte. Es herrschte unvermindert... ► Artikel lesen | |
| NOVAVAX | 5,708 | +0,28 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| BIOGEN | 147,85 | -0,90 % | Biogen stock rated Outperform by RBC Capital with $210 price target | ||
| ILLUMINA | 115,02 | -0,05 % | MyOme, Inc: Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually | Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 47,600 | -0,42 % | Is CRISPR Therapeutics a Buy, Sell, or Hold in 2026? | ||
| MAINZ BIOMED | 1,210 | -1,63 % | Mainz BioMed NV: DoctorBox Adds Mainz Biomed's ColoAlert(R) to Its Portfolio | BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), molecular genetics diagnostic company specializing in the... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,935 | -0,35 % | Viking Therapeutics, Inc. (VKTX): A Bull Case Theory | ||
| INTELLIA THERAPEUTICS | 8,110 | +2,71 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures... ► Artikel lesen | |
| TEMPUS AI | 55,50 | 0,00 % | Tempus AI Approaching Profitability Despite GAAP Losses | ||
| EDITAS MEDICINE | 2,034 | +1,60 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 6,410 | +1,20 % | BIOCRYST PHARMACEUTICALS INC - S-4/A, Registration of securities, business combinations | ||
| BIOMARIN PHARMACEUTICAL | 52,48 | +0,46 % | BioMarin Stock Surges Nearly 20% After $4.8 Bln Amicus Acquisition News | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) shares rose 19.51%, climbing $10.13 to $62.08, after the company announced a definitive agreement to acquire Amicus Therapeutics for... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,890 | -0,42 % | Sarepta-Aktie: Das sind positive Entwicklungen! | Die Aktie von Sarepta Therapeutics hat in den vergangenen Wochen deutlich an Aufmerksamkeit gewonnen, nachdem regulatorische und strategische Entwicklungen neue Perspektiven für das Unternehmen eröffnet... ► Artikel lesen |